Weight and Health Changes With GLP-1 Medicines and Digital Behavior Programs
Follows adults with overweight or obesity using semaglutide, tirzepatide or behavioral programs.
Key facts
- Who runs it
- Noom Inc.
- Where
- Princeton, United StatesSee the site
- Trial code
- Registry title
- GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study
- Status
- Not yet recruiting
- People taking part
- 2,310 people, planned
- Started
- 30 Apr 2026
- Expected to end
- May 2029
- Type of study
- Observational, 8 groups
- Treatments tested
- Noom Weight
- Free Tier
- Education-only control
- Semaglutide
- Tirzepatide
- Microdose semaglutide
- Microdose tirzepatide
- Record updated
- 15 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 64 who speak English and want to lose weight, in a Noom program or an education-only group. It follows weight and health markers over 24 months.
- Age
- 18 Years to 64 Years
- Sex
- All sexes can join.
- Earlier treatment
- No GLP-1 use in the last 24 weeks. Education-only group: not in a structured weight loss or medication program.
Main reasons for not taking part
- Pregnant, breast-feeding, or planning pregnancy during the 12-month program
- Previous or planned bariatric surgery
- Active eating disorder or active cancer
- Type 1 diabetes or current insulin use
- PHQ-8 depression score of 20 or greater
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Speaks English
- Community-dwelling, community-living status
- Able to ambulate independently, with or without aids or devices
- Unless medically indicated, willingness to stay on current program for 12 months and participate in all study activities
- Provides informed consent for study participation
- Commitment and willingness to participate, as assessed by completion of decisional balance exercise
- Program-specific eligibility:
- Medication arms only: Meets standard of care program enrollment criteria for GLP-1 medication. Did not add other products or programs to Noom subscription
- Noom Weight only: Individual who is not interested in medication
- Education-only Control Group: Individual who is interested in weight loss who is not currently enrolled in a structured weight loss program or medication program and does not intend to for the duration of the study Free Tier only: Willingness to use Free Tier
Who cannot take part
- GLP-1 use in the last 24 weeks (prior to Noom program enrollment if in GLP-1 arm)
- Previous or planned (during the 12-month study) bariatric surgery
- Currently taking a medication known to cause weight gain (e.g., antipsychotics, antidepressants, diabetes medication, or corticosteroids)
- Purchased more than the base Noom program offered for participant's specific arm; GLP-1 Medication Arms Only:
- Active eating disorder
- Active cancer
- Type 1 diabetes or current Insulin use
- Personal or family history of medullary thyroid cancer
- Personal or family history of Multiple Endocrine Neoplasia Type 2 (MEN2)
- Personal history of Pancreatitis
- Study screener completed more than 11 days after Noom program enrollment if participating in a Noom program (GLP-1 programs, Noom Weight, and Free Tier)
- Female who is pregnant, breast-feeding, or intends to become pregnant during the 12-month program
- Depression screen results in a PHQ-8 score of 20 or greater; All medicated arms and Noom Weight arms (only):
- GLP-1 agonist use is contraindicated (per program criteria) in members with:
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in United States
- Noom, Inc.Princeton, United StatesContact: Marielle Darwin, PhDNot yet recruiting
About the trial
What the trial wants to find out
This research program includes two coordinated prospective studies (FLOURISH and THRIVE) evaluating the real-world effectiveness of Noom's digital health programs on weight, cardiometabolic biomarkers, physiological health indicators, and program engagement.
Read full original descriptionShow less
FLOURISH is a 6-arm prospective cohort study comparing an Education-only control, Noom Weight, standard-dose compounded semaglutide, microdose compounded semaglutide, standard-dose tirzepatide (Noom Plus), and microdose tirzepatide (Noom Plus Microdose).
THRIVE is a nested 2-arm prospective study comparing a Proactive Health program to a Noom Free Tier control.
Participants complete monthly surveys, remote biomarker collection (Tasso device), connected-scale weigh-ins, and in-app biometric assessments (FaceScan, BodyScan). Microdose and Free Tier arms also use wearable fitness trackers. Primary outcomes are changes in cardiometabolic biomarkers, weight, body composition, and GLP-1 side effect profile. Total N = 2,310; 24-month duration.
The 8 groups in the trial
- Education only (control)
Arm 1 of FLOURISH: This is an active control condition in which participants will receive weekly informational newsletters for 12 months. This group will not have access to the Noom app (except for research purposes) and will not receive GLP-1 medications.
- Noom Weight
Arm 2 of FLOURISH: Noom Weight users will have access to all in-app features. This group will not receive GLP-1 medications. Followed for 12 months.
- Standard GLP-1Rx
Arm 3 of FLOURISH: Standard GLP-1 users will follow a protocol for Noom's standard dose of compounded semaglutide and will have access to all in-app features. Followed for up to 12 months of program with 18 and 24 month follow-up post-GLP-1 discontinuation.
Treatment: Semaglutide
- Microdose GLP-1Rx
Arm 4 of FLOURISH: Microdose GLP-1 users will follow a microdose protocol of compounded semaglutide and will have access to all in-app features. Followed for up to 12 months of program with 18 and 24 month follow-up post-GLP-1 discontinuation.
Treatment: Microdose semaglutide
- Noom Plus
Arm 5 of FLOURISH: Participants will follow a protocol for Noom's standard dose of compounded tirzepatide and will have access to all in-app features. Followed for up to 12 months of program with 18 and 24 month follow-up post-GLP-1 discontinuation.
Treatment: Tirzepatide
- Noom Plus Microdose
Arm 6 of FLOURISH: Noom Plus Microdose users will follow a microdose protocol for compounded tirzepatide and will have access to all in-app features. Followed for up to 12 months of program with 18 and 24 month follow-up post-GLP-1 discontinuation.
Treatment: Microdose tirzepatide
- Noom Free Tier (control)
Arm 1 of THRIVE: This is an active control condition in which users enrolled in Noom's Free Tier program will have access to app features available to Free Tier. This group will not receive GLP-1 medications. Followed for 12 months.
Treatment: Free Tier
- Proactive Health
Arm 2 of THRIVE: Proactive health users will follow the microdose protocol for compounded semaglutide indicated for preventive health/longevity. They will have access to all in-app features. Followed for 12 months.
Treatment: Microdose semaglutide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- GLP-1 Medication & Behavioral Health on Weight and Metabolic Outcomes: FLOURISH (Functional Longitudinal Outcomes Under Intentional Small Habits) & THRIVE (Trajectories of Health, Resilience & Integrated Vitality Evaluation) Cohort Study
- Plain-language title
- Weight and Health Changes With GLP-1 Medicines and Digital Behavior ProgramsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07588984, who can take part
- Record updated
- 15 May 2026